Cargando…

Genes and epigenetic processes as prospective pain targets

Chronic pain affects approximately one in five adults, resulting in a greatly reduced quality of life and a higher risk of developing co-morbidities such as depression. Available treatments often provide inadequate pain relief, but it is hoped that through deeper understanding of the molecular mecha...

Descripción completa

Detalles Bibliográficos
Autores principales: Crow, Megan, Denk, Franziska, McMahon, Stephen B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706821/
https://www.ncbi.nlm.nih.gov/pubmed/23409739
http://dx.doi.org/10.1186/gm416
_version_ 1782276413397663744
author Crow, Megan
Denk, Franziska
McMahon, Stephen B
author_facet Crow, Megan
Denk, Franziska
McMahon, Stephen B
author_sort Crow, Megan
collection PubMed
description Chronic pain affects approximately one in five adults, resulting in a greatly reduced quality of life and a higher risk of developing co-morbidities such as depression. Available treatments often provide inadequate pain relief, but it is hoped that through deeper understanding of the molecular mechanisms underlying chronic pain states we can discover new and improved therapies. Although genetic research has flourished over the past decade and has identified many key genes in pain processing, the budding field of epigenetics promises to provide new insights and a more dynamic view of pain regulation. This review gives an overview of basic mechanisms and current therapies to treat pain, and discusses the clinical and preclinical evidence for the contribution of genetic and epigenetic factors, with a focus on how this knowledge can affect drug development.
format Online
Article
Text
id pubmed-3706821
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37068212014-02-15 Genes and epigenetic processes as prospective pain targets Crow, Megan Denk, Franziska McMahon, Stephen B Genome Med Review Chronic pain affects approximately one in five adults, resulting in a greatly reduced quality of life and a higher risk of developing co-morbidities such as depression. Available treatments often provide inadequate pain relief, but it is hoped that through deeper understanding of the molecular mechanisms underlying chronic pain states we can discover new and improved therapies. Although genetic research has flourished over the past decade and has identified many key genes in pain processing, the budding field of epigenetics promises to provide new insights and a more dynamic view of pain regulation. This review gives an overview of basic mechanisms and current therapies to treat pain, and discusses the clinical and preclinical evidence for the contribution of genetic and epigenetic factors, with a focus on how this knowledge can affect drug development. BioMed Central 2013-02-15 /pmc/articles/PMC3706821/ /pubmed/23409739 http://dx.doi.org/10.1186/gm416 Text en Copyright © 2013 BioMed Central Ltd
spellingShingle Review
Crow, Megan
Denk, Franziska
McMahon, Stephen B
Genes and epigenetic processes as prospective pain targets
title Genes and epigenetic processes as prospective pain targets
title_full Genes and epigenetic processes as prospective pain targets
title_fullStr Genes and epigenetic processes as prospective pain targets
title_full_unstemmed Genes and epigenetic processes as prospective pain targets
title_short Genes and epigenetic processes as prospective pain targets
title_sort genes and epigenetic processes as prospective pain targets
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706821/
https://www.ncbi.nlm.nih.gov/pubmed/23409739
http://dx.doi.org/10.1186/gm416
work_keys_str_mv AT crowmegan genesandepigeneticprocessesasprospectivepaintargets
AT denkfranziska genesandepigeneticprocessesasprospectivepaintargets
AT mcmahonstephenb genesandepigeneticprocessesasprospectivepaintargets